New Delhi: Pharma major Biocon Tuesday said the company retains economic interest in global commercialisation of Hulio in-licensed by Mylan. "Following the successful approval and European launch of Hulio, (biosimilar Adalimumab) in-licensed by our partner Mylan from Fujifilm Kyowa Kirin Biologics, the commercialisation rights have been extended from Europe to global markets," it said in a regulatory filing.

Biocon, under the terms of its global partnership with Mylan for monoclonal antibodies, retains its economic interest in this expanded in-licensing arrangement and will gain a share of profits from global markets, it said.

"Biocon is committed to enable patient access to affordable biosimilars and this partnership accelerates that process," Biocon spokesperson said in the filing.